Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib [Phase 3]
Phase 3 trial comparing MRD-guided maintenance therapy with gilteritinib versus sorafenib after allogeneic hematopoietic cell transplantatio…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial [Phase 4]
A Phase 4 randomized trial is evaluating an intensified conditioning regimen combining ruxolitinib and decitabine for patients with acute my…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies [Phase 4]
Phase 4 trial evaluating olutasidenib for drug-drug interaction in IDH1-mutant malignancies. The study is currently recruiting in AML, gliom…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies [Phase 2]
Phase 2 pilot study to assess feasibility of using decitabine with filgrastim as post-transplant prophylaxis in children and young adults wi…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]
A Phase 2 trial update describes a new double epigenetic regimen being studied in relapsed or refractory acute myeloid leukemia, with the st…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: VAC Regimen for AML Patients Who Failed to Response to VA Regimen [Phase 2]
Clinical trial update for a Phase 2 VAC regimen in AML patients who did not respond to VA regimen; currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Ziftomenib Maintenance Post Allo-HCT [Phase 1]
A Phase 1 trial evaluating Ziftomenib as maintenance therapy after allogeneic hematopoietic cell transplantation in acute myeloid leukemia (…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients [Phase 2]
Phase 2 trial evaluating maintenance therapy with a hypomethylating agent in favorable-risk acute myeloid leukemia patients is currently rec…
-
CLINICAL_TRIALS research · 2026-03-19Clinical Trial Update: HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
HEM-SURVIVE is a structured follow-up study for childhood survivors of hematologic malignancies; the trial is currently NOT_YET_RECRUITING a…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
A clinical trial update evaluating the AlloHeme test for assessing chimerism and detecting relapse after bone marrow/hematopoietic cell tran…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation [Phase 1, Phase 2]
A phase 1/2 trial evaluating Revumenib in relapsed/refractory leukemias including MLL/KMT2A rearrangements or NPM1 mutations; currently recr…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) [Phase 3]
This entry describes a Phase 3 clinical trial (VENP-A-QUI) evaluating azacitidine and venetoclax with or without quizartinib as first-line t…
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: CIML NK Cells With Venetoclax for AML [Phase 1]
Phase 1 clinical trial of CIML NK Cells with Venetoclax for Acute Myeloid Leukemia is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-18Clinical Trial Update: Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS [Phase 1]
Phase 1 clinical trial evaluating a combination of epigenetic therapy and sensitising therapy in acute myeloid leukemia, myelodysplastic syn…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial [Phase 3]
A Phase 3 randomized trial assessing whether adding venetoclax to the fludarabine/melphalan conditioning regimen improves outcomes for adult…
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation [Phase 2]
This Phase 2 clinical trial protocol investigates a post-transplant cyclophosphamide–based graft-versus-host disease prophylaxis approach in…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms [Phase 2]
A Phase 2 clinical trial evaluating decitabine in combination with JAK inhibitors (ruxolitinib, fedratinib, or pacritinib) for accelerated o…
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML [Phase 1, Phase 2]
A study of SLS009 (formerly GFH009), a potent CDK9 inhibitor, in hematologic malignancies including high-risk newly diagnosed acute myeloid …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias [Phase 1]
Clinical trial update for CBX-250 in relapsed or refractory myeloid leukemias (Phase 1) that is currently recruiting at Crossbow Therapeutic…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients [Phase 2]
Phase 2 study evaluating de-escalation by discontinuing venetoclax and azacitidine in AML patients who are responding to therapy.
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation [Phase 1]
Phase 1 trial evaluating the combination of SNDX-5613 and gilteritinib for relapsed or refractory FLT3-mutated acute myeloid leukemia, inclu…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms [NA]
This clinical trial update describes a randomization study to identify the best treatment intensity for less fit adults with acute myeloid l…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation [Phase 2]
A Phase 2 clinical trial is evaluating enasidenib as maintenance therapy after allogeneic stem cell transplantation in patients with IDH2-mu…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML [Phase 2]
Phase 2 global trial evaluating safety, efficacy, and pharmacokinetics of midostaurin in combination with chemotherapy for newly diagnosed p…
-
CLINICAL_TRIALS research · 2026-03-13Clinical Trial Update: Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy [Phase 2]
This clinical trial update reports a Phase 2 study of ziftomenib for patients with NPM1-mutated or KMT2A-rearranged acute myeloid leukemia w…